Rodriguez-Arboli, EduardoMartinez-Cuadron, DavidRodriguez-Veiga, RebecaCarrillo-Cruz, EstrellaGil-Cortes, CristinaSerrano-Lopez, JosefinaBernal Del Castillo, TeresaMartinez-Sanchez, Maria Del PilarRodriguez-Medina, CarlosVidriales, BelenBergua, Juan MiguelBenavente, CelinaGarcia-Boyero, RaimundoHerrera-Puente, PilarAlgarra, LorenzoSayas-Lloris, Maria JoseFernandez, RosaLabrador, JorgeLavilla-Rubira, EsperanzaBarrios-Garcia, ManuelTormo, MarSerrano-Maestro, AlfonsSossa-Melo, Claudia LuciaGarcia-Belmonte, DanielVives, SusanaRodriguez-Gutierrez, Juan IgnacioAlbo-Lopez, CarmenGarrastazul-Sanchez, Maria PazColorado-Araujo, MercedesMariz, JoseSanz, Miguel AngelPerez-Simon, Jose AntonioMontesinos, Pau2023-02-092023-02-092020-12-24Rodríguez-Arbolí E, Martínez-Cuadrón D, Rodríguez-Veiga R, Carrillo-Cruz E, Gil-Cortés C, Serrano-López J, et al. Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study. Transplant Cell Ther. 2021 Apr;27(4):311.e1-311.e10http://hdl.handle.net/10668/17556Acute myeloid leukemia (AML) with intermediate risk cytogenetics (IRcyto) comprises a variety of biological entities with distinct mutational landscapes that translate into differential risks of relapse and prognosis. Optimal postremission therapy choice in this heterogeneous patient population is currently unsettled. In the current study, we compared outcomes in IRcyto AML recipients of autologous (autoSCT) (n = 312) or allogeneic stem cell transplantation (alloSCT) (n = 279) in first complete remission (CR1). Molecular risk was defined based on CEBPA, NPM1, and FLT3-ITD mutational status, per European LeukemiaNet 2017 criteria. Five-year overall survival (OS) in patients with favorable molecular risk (FRmol) was 62% (95% confidence interval [CI], 50-72) after autoSCT and 66% (95% CI, 41-83) after matched sibling donor (MSD) alloSCT (P = .68). For patients of intermediate molecular risk (IRmol), MSD alloSCT was associated with lower cumulative incidence of relapse (PenAcute myeloid leukemiaAllogeneic stem cell transplantAutologous stem cell transplantCytogenetic AnalysisHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteNucleophosminRemission InductionTransplantation, Homologousresearch article33836871open accessAnálisis citogenéticoInducción de remisiónLeucemia mieloide agudaNucleofosminaTrasplante homólogoTrasplante de células madre hematopoyéticas10.1016/j.jtct.2020.12.0292666-6367https://doi.org/10.1016/j.jtct.2020.12.029